肾细胞癌中的治疗性疫苗
Therapeutic vaccines in renal cell carcinoma.
作者信息
Schwaab Thomas, Ernstoff Marc S
机构信息
Department of Urology & Department of Immunology, Roswell Park CancerInstitute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
出版信息
Therapy. 2011 Jul;4(8):369-377. doi: 10.2217/thy.11.40.
Abstract
Metastatic renal cell carcinoma (mRCC) is a lethal disease. The advent of tyrosine kinase inhibitors (TKIs) has changed the disease process, yet the majority of patients will develop treatment-resistant disease. IL-2 based immunotherapy in mRCC is the only US FDA-approved treatment with curative results. Immunotherapeutic vaccine approaches to mRCC have been under investigation for several decades with mixed results. The recent FDA-approval of the first cellular immunotherapy in prostate cancer (Provenge(®)) has reinvigorated the search for similar vaccines approaches in mRCC. This review introduces the concepts and different features required for a successful anticancer vaccine approach.
摘要
转移性肾细胞癌（mRCC）是一种致命疾病。酪氨酸激酶抑制剂（TKIs）的出现改变了疾病进程，但大多数患者仍会发展为耐药性疾病。基于白细胞介素-2的免疫疗法是美国食品药品监督管理局（FDA）批准的唯一对mRCC有治愈效果的疗法。针对mRCC的免疫治疗疫苗方法已经研究了几十年，结果不一。最近FDA批准了首款用于前列腺癌的细胞免疫疗法（Provenge(®)），这重新激发了在mRCC中寻找类似疫苗方法的研究热情。本综述介绍了成功的抗癌疫苗方法所需的概念和不同特征。
相似文献
1
Therapeutic vaccines in renal cell carcinoma.肾细胞癌中的治疗性疫苗
Therapy. 2011 Jul;4(8):369-377. doi: 10.2217/thy.11.40.
2
Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.在现代酪氨酸激酶抑制剂和免疫检查点抑制剂时代，转移性肾细胞癌患者的总生存率提高：一项基于奥地利人群的真实研究结果，随访长达三十年。
Ther Adv Med Oncol. 2022 Nov 19;14:17588359221134065. doi: 10.1177/17588359221134065. eCollection 2022.
3
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.免疫疗法正在改变转移性肾细胞癌的一线治疗方法。
Clin Genitourin Cancer. 2019 Jun;17(3):e513-e521. doi: 10.1016/j.clgc.2019.01.017. Epub 2019 Feb 5.
4
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.肾细胞癌的免疫治疗靶点与疗法
Immunotargets Ther. 2020 Nov 13;9:273-288. doi: 10.2147/ITT.S240889. eCollection 2020.
5
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.一线免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗肾细胞癌患者的生存与临床病理特征的关系：一项随机临床试验的荟萃分析。
Eur Urol Focus. 2022 Mar;8(2):514-521. doi: 10.1016/j.euf.2021.03.001. Epub 2021 Mar 11.
6
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.酪氨酸激酶抑制剂与免疫疗法联合用于肾细胞癌的治疗
Ther Adv Med Oncol. 2020 Mar 18;12:1758835920907504. doi: 10.1177/1758835920907504. eCollection 2020.
7
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.脊柱立体定向放射外科联合酪氨酸激酶抑制剂治疗转移性肾细胞癌。
J Neurosurg Spine. 2016 Dec;25(6):766-774. doi: 10.3171/2016.4.SPINE16229. Epub 2016 Jul 8.
8
Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.二线免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗转移性肾细胞癌患者的疗效：一项真实世界研究。
Immunotherapy. 2022 Apr;14(5):309-320. doi: 10.2217/imt-2021-0108. Epub 2022 Feb 21.
9
Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations.对比具有横纹肌样和肉瘤样分化的转移性肾细胞癌的酪氨酸激酶抑制剂治疗。
Cancer Med. 2023 Jul;12(13):14149-14156. doi: 10.1002/cam4.6081. Epub 2023 Jun 16.
10
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.转移性肾细胞癌患者一线和二线酪氨酸激酶抑制剂之间不良事件无显著相关性。
Clin Genitourin Cancer. 2016 Feb;14(1):e19-24. doi: 10.1016/j.clgc.2015.08.002. Epub 2015 Aug 15.
引用本文的文献
1
Lipids as Targets for Renal Cell Carcinoma Therapy.脂质作为肾癌治疗的靶点。
Int J Mol Sci. 2023 Feb 7;24(4):3272. doi: 10.3390/ijms24043272.
2
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities.转移性肾细胞癌：流行病学、遗传学及治疗方式的最新进展
Immunotargets Ther. 2013 Jul 22;2:73-90. doi: 10.2147/ITT.S31426. eCollection 2013.
3
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.人抗CAIX抗体在体外以及在人源化小鼠体内模型中介导免疫细胞对肾细胞癌的抑制作用。
Mol Cancer. 2015 Jun 11;14:119. doi: 10.1186/s12943-015-0384-3.
4
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.优化免疫治疗药物（如 sipuleucel-T）在前列腺癌中的临床效果的策略。
J Natl Compr Canc Netw. 2012 Dec 1;10(12):1505-12. doi: 10.6004/jnccn.2012.0156.
本文引用的文献
1
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.抗体靶向 NY-ESO-1 与甘露糖受体或 DEC-205 在体外可引发具有广泛抗原特异性的双重人 CD8+和 CD4+T 细胞反应。
J Immunol. 2011 Jan 15;186(2):1218-27. doi: 10.4049/jimmunol.1000808. Epub 2010 Dec 13.
2
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.一项在结直肠癌患者中进行的树突状细胞疫苗体外 CD40L 激活的随机试验：肿瘤特异性免疫应答与改善的生存相关。
Clin Cancer Res. 2010 Nov 15;16(22):5548-56. doi: 10.1158/1078-0432.CCR-10-2138. Epub 2010 Sep 30.
3
Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation?微调 CD8(+) T 细胞功能反应：mTOR 作为调节 CD8(+) T 细胞增殖、存活和分化的变阻器？
Cell Cycle. 2010 Aug 1;9(15):2996-3001. doi: 10.4161/cc.9.15.12359. Epub 2010 Aug 12.
4
Targeted treatment for metastatic renal cell carcinoma and immune regulation.转移性肾细胞癌的靶向治疗与免疫调节
J BUON. 2010 Apr-Jun;15(2):235-40.
5
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.一项在转移性肾细胞癌患者中使用单克隆抗体 cG250（RENCAREX®）和干扰素-α-2a 的临床 I/II 期试验。
World J Urol. 2011 Feb;29(1):121-6. doi: 10.1007/s00345-010-0570-2. Epub 2010 May 30.
6
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. survivin 肽模拟物诱导的抗肿瘤细胞毒性 T 细胞应答。
Cancer Immunol Immunother. 2010 Aug;59(8):1211-21. doi: 10.1007/s00262-010-0845-x. Epub 2010 Apr 27.
7
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
8
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.采用痘病毒 PSA 疫苗治疗转移性去势抵抗性前列腺癌的总生存相关免疫和预后因素。
Cancer Immunol Immunother. 2010 May;59(5):663-74. doi: 10.1007/s00262-009-0782-8. Epub 2009 Nov 5.
9
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.自体肿瘤裂解物疫苗辅助治疗肾癌患者的 10 年生存分析。
Cancer Immunol Immunother. 2010 May;59(5):687-95. doi: 10.1007/s00262-009-0784-6. Epub 2009 Oct 30.
10
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.基于T细胞的转移性肾细胞癌免疫疗法：取得一定成功及未来展望
Clin Cancer Res. 2009 Nov 1;15(21):6503-10. doi: 10.1158/1078-0432.CCR-09-1605. Epub 2009 Oct 20.
Zotero 插件